| Non-Human Toxicity Excerpts | /LABORATORY ANIMALS: Acute Exposure/ beta-Asarone doubled sleeping time with sodium pentobarbital in mice at a dose of 50 mg/kg bw i.p. and doubled the sleeping time with ethanol at a dose of 75 mg/kg. /beta-Asarone//LABORATORY ANIMALS: Acute Exposure/ ... a study was conducted of the biological properties of alpha-asarone (1-propenyl-2,4,5- methoxybenzol)--etherophenol, isolated by the authors from the roots of Asarum europaeum. It was determined that the LD50 of asarone for mice in enteral administration was 417.6 mg/kg, in intra-abdominal 310 mg/kg .../LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ ... The drug alpha-asarone (3, 6 and 9 mg/kg bw, ip, for 30 days) ... was administered intraperitoneally 1/2 hr before the animals were exposed to noise-stress (100 dB for 4 hr/day, for 30 days) . ... All the three doses of alpha-asarone had an effectively protective role, by normalizing the increased superoxide dismutase and lipid peroxidation, decreased catalase, glutathione peroxidase, levels of reduced glutathione, Vitamins C and E and protein thiols due to noise exposure. Thus, action of alpha-asarone against noise-stress may be due its antioxidant property .../LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Groups of 25 male and 25 female rats were fed diets containing 0, 400, 800, or 2000 ppm (0, 0.04, 0.08, or 0.2%) beta-asarone for two years. A positive control group of the same size received 2500 ppm (0.25%) Jammu oil of calamus (JOC/approx. 75% beta-asarone/). None of the group receiving 2000 ppm (0.2%) beta-asarone or 2500 ppm (0.25%) JOC survived more than 84 weeksmortality was also increased on the 800 ppm (0.08%) dose. Median survival time in the females was less than in the males in these groups. The gross pathological changes observed were serous fluid in the abdominal and pleural cavities, liver and kidney changes, and tumourous masses in the intestinal tract. The tumors were identified as leiomyosarcomas of the small intestine and were found in one rat on 400 ppm (0.04%), six on 800 ppm (0.08%), nine on 2000 ppm (0.2%) and one on 2500 ppm (0.25%) JOC. All the test rats with leiomyosarcomas were males. The earliest tumor was observed in a rat 52 weeks old on the 2000 ppm (0.2%) dose. Two leiomyosarcomas were also noted in control females but the location differed from that of the tumors in the treated animals. Atrophy of cardiac muscle cells occurred in controls and all test groups but was most prominent in the 2000 ppm (0.2%) beta-asarone and 2500 ppm (0.25%) JOC groups. Cardiac fibrosis generally paralleled the incidence of cardiac atrophy. Fatty degeneration and fatty infiltration were also in the heart more severe in the treated groups. Thrombosis within the chambers of the heart was observed in the 800 and 2000 ppm (0.08 and 0.27%) beta-asarone and 2500 ppm (0.25%) JOC treated groups. Passive hyperemia of the lung, kidneys and liver was more prominent in the test than control animals indicating faulty cardiac function in the test animals. Incidence of hepatic angiectasis and hepatic coagulative necrosis also tended to increase with increasing beta-asarone dose. Both sexes on 800 and 2000 ppm (0.08 and 0.2%) beta-asarone and 2500 ppm (0.25%) JOC had slightly depressed body weights throughout the studythe males on 400 ppm (0.04%) ß-asarone also had depressed body weights at termination but the number of survivors was small. Hemoglobin, hematocrit, and red and white cell counts were normal except that when the test animals became sick they became anemic with lowered hemoglobin, hematocrit, and red cell count. /beta-Asarone/For more Non-Human Toxicity Excerpts (Complete) data for TRANS-ASARONE (14 total), please visit the HSDB record page. |
|---|
